SCHEMBL14966166

SCHEMBL14966166

O=C(c1ccc(CN2CCN(C3CCN(c4ncc(C(F)(F)F)cc4F)CC3)C2=O)cc1)N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.44
CHRM4 P08173 1/20 0.43
KCNH2 Q12809 2/20 0.42
CHRM2 P08172 2/20 0.42
CHRM1 P11229 2/20 0.42
CHRM3 P20309 2/20 0.42
CHRM5 P08912 1/20 0.42
HIF1A Q16665 1/20 0.42
EPAS1 Q99814 1/20 0.42
PRKAA2 P54646 1/20 0.40
HPGD P15428 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CASP1 P29466 1/20 0.40
HTT P42858 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC6A9 P48067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14966344 0.93 CHRM4 (0.44) HRH3CHRM4CHRM2CHRM1CHRM3
SCHEMBL14966417 0.91 CHRM4 (0.43) CHRM4CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966225 0.88 CHRM4 (0.42) CHRM4CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966593 0.88 CHRM4 (0.42) CHRM4CHRM2CHRM1CHRM3CHRM5
SCHEMBL14978741 0.88 CHRM4 (0.42) CHRM4CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966608 0.88 CHRM4 (0.47) CHRM4CHRM2CHRM1CHRM3CHRM5
SCHEMBL14966485 0.88 KCNH2 (0.46) CHRM4KCNH2CHRM2CHRM1CHRM3
SCHEMBL14978707 0.88 KCNH2 (0.46) CHRM4KCNH2CHRM2CHRM1CHRM3
SCHEMBL14966489 0.88 KCNH2 (0.46) CHRM4KCNH2CHRM2CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL16163081 0.85 KCNH2 (0.44) CHRM4KCNH2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2014-10-16 US disclosed
WO-2013074641-A1 PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2013-05-23 WO disclosed
WO-2013074641-A1 PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309226-A1 PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS GPR119, UTS2R, GPR139 HRH3 209/4885CHRM4 357/4885KCNH2 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.